“Antimicrobials really aren't getting the love lately,” said Dr. Vu Truong, CEO of Aridis Pharmaceuticals (Nasdaq: ARDS) as he reviewed the latest data on his own company's antimicrobial treatment for COVID-19. “But COVID may wind up changing that.”
